Bioaxia Life Sciences Fund LP has filed an amendment to its private offering, detailing compliance with SEC regulations. This update is crucial for the company as it continues to operate within the pooled investment fund sector, specifically focusing on hedge fund strategies.
Background
Bioaxia Life Sciences Fund LP is a limited partnership based in New York, incorporated in Delaware. The company focuses on pooled investment funds and operates under the SEC Act of 1933. Its recent filings include a Form D/A on October 27, 2026, and a Form D on September 15, 2025.
What the Filing Says
The filing indicates that the amendment is related to Rule 506(b), which provides a safe harbor for private offerings. It also mentions compliance with Investment Company Act Section 3(c) and Section 3(c)(7). The effectiveness date of this amendment is noted as October 27, 2026.
Impact
This update may affect accredited investors and those interested in hedge fund opportunities. The fund has already attracted six investors, and it does not accept non-accredited investors.
What's Next
The filing does not say what happens next.
Offering Details
The amendment provides additional details about the offering, indicating that the total offering amount is classified as indefinite, with a total amount already sold reported at $3,260,000. The fund has a minimum investment requirement of $500,000, which is aimed at ensuring that only accredited investors participate.
Investor Composition
Currently, Bioaxia Life Sciences Fund LP has attracted six investors, all of whom are accredited and meet the criteria set forth in the SEC regulations. The fund does not accept investments from non-accredited investors, reinforcing its focus on a select group of high-net-worth individuals or institutional investors.
Management and Fees
The fund charges a management fee, which is detailed in its governing documents. However, the filing does not disclose the specific percentage or structure of this fee. Additionally, there are no sales commissions or finders' fees associated with this offering, as indicated by the dollar amounts reported as zero in the filing.
Use of Proceeds
While the filing notes that the gross proceeds used are estimated to be $0, it emphasizes that the fund's management fee is outlined in the governing documents, suggesting that proceeds may be allocated towards operational expenses and management activities.
Related Persons
The filing identifies key individuals associated with the fund, including Douglas Eby, who serves as the Managing Member of the General Partner of the Issuer. Additionally, Bioaxia Life Sciences Fund GP LLC and Bioaxia LLC are noted as related entities, with roles as the Executive Officer and Investment Manager, respectively.
Future Filings
The filing does not provide information regarding future fundraising efforts or additional amendments that may be anticipated. It remains unclear whether the fund plans to expand its investor base or adjust its investment strategy moving forward.